By targeting the application of our novel technologies towards areas of global unmet medical need, Aurum strives to provide healthcare improvements worldwide, resulting in significant societal benefits at both the patient and healthcare provider level. Through a number of strategic local and international collaborations, our highly experienced team aims to deliver the first major advancement in the management of all acute ischaemic stroke patients in the past 20 years. At Aurum we continually endeavour to maximize value for our investors by developing our pipeline of novel drug and diagnostic agents.
Aurum’s strategy is to build a pipeline of innovative products that addresses targeted unmet medical needs, thus improving treatment options for patients and physicians alike while simultaneously adding value to our shareholders’ investment. Our first target is Acute Ischaemic Stroke (AIS). The pre-clinical studies are in the final stages of completion, allowing us to directly enter into a Phase 2a trial in stroke patients in the near future. A full clinical programme will follow. In parallel, Aurum is developing its pipeline products for other therapeutic areas of high unmet medical need.